Use of Specially Designed Pediatric MR Coils on Clinical Scanners
Novel Coils for Pediatric Musculoskeletal MRI
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Healthy Participants:
- Male or female
- Age: Old enough to participate in an MR study without sedation (typically greater than 5-6 years old)
Pediatric Patients:
- Male or female
- Sent for elbow MR or superficial/small parts musculoskeletal MR imaging.
- Age: any age
Exclusion Criteria:
- Female participants who are pregnant or lactating (verbal pregnancy screens will be given for all females of child bearing potential prior to the MRI).
- Subjects with standard contraindications to MRI.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy Volunteers
Research only musculoskeletal (MSK) MRI for healthy volunteers.
|
Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
|
|
Clinical Efficacy
Clinically indicated musculoskeletal (MSK) MRI with sequences obtained using this pediatric elbow coil.
|
Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with adverse events as measured by heating and comfort participant response.
Time Frame: Day 1
|
Each participant will be monitored for adverse events during the MRI scan
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MRI Image Quality
Time Frame: Up to 3 weeks post MRI participant scan
|
The following measures will be individually evaluated on 3-point scale: Overall image quality, Image uniformity overall, and Signal to Noise.
|
Up to 3 weeks post MRI participant scan
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kathleen Emery, M.D., Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2011-2154
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.